Order Article Reprints

Basile V, Puglisi S, Altieri B, Canu L, Libè R, Ceccato F, Beuschlein F, Quinkler M, Calabrese A, Perotti P, et al. What Is the Optimal Duration of Adjuvant Mitotane Therapy in Adrenocortical Carcinoma? An Unanswered Question. Journal of Personalized Medicine. 2021; 11(4):269. https://doi.org/10.3390/jpm11040269

Basile, Vittoria, Soraya Puglisi, Barbara Altieri, Letizia Canu, Rossella Libè, Filippo Ceccato, Felix Beuschlein, Marcus Quinkler, Anna Calabrese, Paola Perotti, and et al. 2021. "What Is the Optimal Duration of Adjuvant Mitotane Therapy in Adrenocortical Carcinoma? An Unanswered Question" Journal of Personalized Medicine 11, no. 4: 269. https://doi.org/10.3390/jpm11040269

Basile, V., Puglisi, S., Altieri, B., Canu, L., Libè, R., Ceccato, F., Beuschlein, F., Quinkler, M., Calabrese, A., Perotti, P., Berchialla, P., Dischinger, U., Megerle, F., Baudin, E., Bourdeau, I., Lacroix, A., Loli, P., Berruti, A., Kastelan, D., ... Terzolo, M. (2021). What Is the Optimal Duration of Adjuvant Mitotane Therapy in Adrenocortical Carcinoma? An Unanswered Question. Journal of Personalized Medicine, 11(4), 269. https://doi.org/10.3390/jpm11040269